HDAC9 and leukemia: Of note, the combination of PI and HDAC inhibitor is being evaluated in a recent clinical trial of MLL-rearranged leukemia (NCT02553460), which demonstrated the promising efficacy of this combinational therapy strategy and the high clinical relevance of our study [20].